NBIX News and Press, Neurocrine Biosciences Inc. From 07/19/21

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results Conference Call and Webcast Scheduled for Tuesday, August 3 PR Newswire SAN DIEGO , July 19, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: ...

Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference PR Newswire SAN DIEGO , July 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Kyle Gano , Chief Business Development and Strategy ...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

I will share an update on the last two years of progress. An update on future milestones will be outlined. I will give investors a rudimentary outline for near-term revenues expected for Idorsia. For further details see: Idorsia: Putting The Capstone On A Foundationally ...

Today, we look in on Voyager Therapeutics for the first time in many, many years. This small biotech concern is using the adeno-associated virus or AAV approach to develop its gene therapy candidates. A full investment analysis follows in the paragraphs below. For ...

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...

Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference PR Newswire SAN DIEGO , June 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42 nd Annual Global Healthc...

My Roth IRA portfolio of 29 CEFs and 30 REITs for income, and 119 stocks for swing trading under-performing S&P 500 stocks, continues to realize profits. In May, I closed 8 stock trades for a net gain, including dividends, of 38.79% (median) or 34.65% (cost-weighted), for an avera...

Neurocrine once again posted disappointing Ingrezza sales, and while the post-pandemic reopening should help, it likely won't be an immediate recovery. Management is advancing a broad pipeline of high-risk/high-reward candidates into Phase II studies for a range of movement and psychi...